Embryonic Ploidy Status in the Oncofertility Population
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Oncology
- Sponsor
- Reproductive Medicine Associates of New Jersey
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- embryonic aneuploidy rates
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
looking at aneuploidy rates in embryos from patients who are going to or have undergone treatment for a malignancy with gonadotoxic treatment.
Detailed Description
The study involves oncofertility patients--individuals who are undergoing or have undergone therapy for a malignancy--who are interested in pursuing or preserving fertility. In particular, it investigates chromosomal abnormalities or aneuploidy in the embryos of those individuals as compared to the general infertility population. Embryonic aneuploidy is largely due to reproductive senescence. As such the investigators will discuss oncofertility prevalence and treatment as well as reproductive senescence and assessment of embryonic aneuploidy. The study will seek to determine if there are changes in embryonic aneuploidy rates in oncofertility patients that differ from simple age related risks.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1.Present or past oncologic diagnosis requiring potentially gonadotoxic treatment
Exclusion Criteria
- •Oocyte banking
- •Use of oocyte donation
- •Any contraindications to undergoing in vitro fertilization or gonadotropin stimulation
- •Single gene disorder requiring more detailed embryo genetic analysis
Outcomes
Primary Outcomes
embryonic aneuploidy rates
Time Frame: 1 month
to evaluate the incidence of embryonic aneuploidy among oncofertility patients compared to the general infertility population